SAN ANTONIO - A drug effective in the treatment of breast cancer has shown new promise in treating brain tumors that stem from the disease.
A new trial report released by the University of Texas Health Science Center San Antonio reveals that the drug, sacituzumab govitecan, shows new promise in addressing breast cancer with brain metastases or recurrent glioblastoma.
These findings resulted from a prospective "window-of-opportunity" trial in which patients agreed to receive a novel treatment before undergoing surgery.
Researchers found that the drug was well tolerated and showed signs of effectiveness for those whose breast cancer had progressed to brain tumors.
“We knew that the drug has been effective in the treatment of breast cancer, but its usefulness in treatment of resulting brain tumors has been unclear,” said Andrew J. Brenner, MD, PhD, professor and chair of neuro-oncology research with Mays Cancer Center at UT Health San Antonio. “Our trial, however, revealed that it could achieve concentrations of inhibitors inside the tumors sufficient to benefit patients, and with minimal side effects, which is very promising for new therapy.”
About half of all women with the aggressive and advanced triple-negative form of breast cancer will be diagnosed with brain metastases, the report details. The prognosis is poor, with a median overall survival of just more than seven months.
ncG1vNJzZmihlJa1sLrEsKpnm5%2BifK%2Bx1qxmp5mknryvedaoqaWcX6rBbrTEmqOtoF2Zv7azjKyfqK%2BjYr2zu8yiqp5llqS%2FbsDRnpitoZ6ceqO%2BwKKlZqyloryzv4ysq56lnZ67qHnFq6amZZKnsqK%2F02aamqaTmr9uv8KinKeblWLAtr7GnqmyZaKavbC%2B02ajqJuRoXqvsdasZKedkad6rrE%3D